Forte Biosciences, Inc.
public_traded
Forte Biosciences, Inc. is publicly traded on NASDAQ under ticker FBRX.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.